AstraZeneca unveils $15bn China investment during Keir Starmer visit
The UK pharmaceutical giant has announced a landmark $15bn China investment during the UK prime minister’s visit, marking its largest expansion yet to boost manufacturing, R&D and biotech collaboration.
Koichiko
February 01, 2026
UK pharmaceutical giant AstraZeneca has unveiled a five-year $15 billion investment plan in China through 2030 to expand medicines manufacturing and research and development (R&D), as UK prime minister Keir Starmer visited China at the end of January.
¬ Haymarket Media Limited. All rights reserved.
Sign in to read on!
Registered users get 2 free articles in 30 days.
Subscribers have full unlimited access to FinanceAsia.
Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.
Questions?
See here for more information on licences and prices, or contact [email protected].
.jpg&h=630&w=1200&q=100&v=ebcc31501f&c=1)
